<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707703</url>
  </required_header>
  <id_info>
    <org_study_id>200639</org_study_id>
    <nct_id>NCT04707703</nct_id>
  </id_info>
  <brief_title>Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis</brief_title>
  <acronym>Isavu-CAPA</acronym>
  <official_title>Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Jenks, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate whether antifungal prophylaxis with isavuconazole&#xD;
      can reduce the incidence of SARS-CoV-2-associated invasive aspergillosis in patients in the&#xD;
      ICU (intensive care unit) with severe COVID-19 infection.&#xD;
&#xD;
      The investigators will perform an interventional, double-blinded, randomized-controlled,&#xD;
      multi-center study in patients with severe COVID-19 infection admitted to the ICU. Patients&#xD;
      will be randomized to the isavuconazole prophylaxis plus standard of care (SOC) group or the&#xD;
      placebo plus SOC group. Participants will receive isavuconazole or placebo for up to 28 days&#xD;
      or until discharge from the hospital (whichever occurs first).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 (COVID-19) infection&#xD;
      without a diagnosis of invasive aspergillosis who are hospitalized in the ICU are eligible&#xD;
      for inclusion in this study and will be randomized to the isavuconazole plus standard of care&#xD;
      (SOC) group or placebo plus SOC group.&#xD;
&#xD;
      If randomized to the isavuconazole group, participants will receive intravenous&#xD;
      isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous&#xD;
      isavuconazonium sulfate 372 mg once daily for up to 28 days. If randomized to the placebo&#xD;
      group, participants will receive intravenous placebo every 8 hours for 6 doses followed by&#xD;
      once daily for up to 28 days. Both groups will receive the usual SOC.&#xD;
&#xD;
      Following randomized to the two treatment arms, participants will be screened for invasive&#xD;
      aspergillosis with thrice weekly fungal cultures from tracheal aspirate (TA) secretions or&#xD;
      thrice weekly serum galactomannan (GM) testing (if TA unable to be performed,&#xD;
      contraindicated, or participant is not intubated). If invasive aspergillosis or other&#xD;
      invasive fungal infection is detected, antifungal therapy will be initiated (if the&#xD;
      participant is in the placebo arm) or modified if needed (if the participant is in the&#xD;
      isavuconazole arm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of SARS-CoV-2-associated invasive aspergillosis at time of ICU discharge</measure>
    <time_frame>From date of admission in ICU assessed up to ICU discharge, approximately 28 days</time_frame>
    <description>A patient with SARS-CoV-2-associated invasive aspergillosis is defined as a patient having COVID-19 infection needing intensive care, mycological evidence of Aspergillus and compatible radiological abnormalities consistent with pulmonary aspergillosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of SARS-CoV-2-associated non-Aspergillus invasive fungal infections at time of ICU discharge</measure>
    <time_frame>From date of admission in ICU assessed up to ICU discharge, approximately 28 days</time_frame>
    <description>A patient with SARS-CoV-2-associated non-Aspergillus invasive fungal infection is defined as a patient having COVID-19 infection needing intensive care, mycological evidence of a non-Aspergillus invasive fungal infection, and compatible radiological abnormalities consistent with non-Aspergillus invasive fungal infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>From date of admission in ICU assessed up to ICU discharge, approximately 28 days</time_frame>
    <description>Compare the rates of survival at time of discharge from the ICU in those who receive isavuconazole compared to those who receive placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>From date of admission in ICU assessed up to ICU discharge, approximately 28 days</time_frame>
    <description>Compare the length of ICU stay in those who receive isavuconazole compared to those who receive placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital stay</measure>
    <time_frame>From date of admission in ICU assessed up to hospital discharge, approximately 32 days</time_frame>
    <description>Compare the length of hospital stay in those who receive isavuconazole compared to those who receive placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At 30 and 90 days</time_frame>
    <description>Compare the mortality rate at 30 and 90 days in those who receive isavuconazole compared to those who receive placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From date of start of isavuconazole or placebo through duration of isavuconazole or placebo, approximately 28 days</time_frame>
    <description>Compare the rates of adverse events in those who receive isavuconazole compared to those who receive placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <condition>Aspergillosis Invasive</condition>
  <arm_group>
    <arm_group_label>SOC plus Isavuconazonium sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC plus intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by 372mg once daily for up to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SOC plus intravenous placebo every 8 hours for 6 doses followed by once daily for up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isavuconazonium Injection [Cresemba]</intervention_name>
    <description>Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days</description>
    <arm_group_label>SOC plus Isavuconazonium sulfate</arm_group_label>
    <other_name>Isavuconazole</other_name>
    <other_name>Cresemba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days</description>
    <arm_group_label>SOC plus Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from the patient or his/her legally authorized&#xD;
             person.&#xD;
&#xD;
          -  Adult patient (&gt; 18 years).&#xD;
&#xD;
          -  PCR-confirmed SARS-CoV-2 based on nasopharyngeal swab (NPS), oropharyngeal swab (OPS),&#xD;
             tracheal aspirate (TA), bronchial aspirate (BA), or bronchoalveolar lavage fluid&#xD;
             (BALF) within 14 days prior to ICU admission or within 72 hours following ICU&#xD;
             admission.&#xD;
&#xD;
          -  Radiographic imaging consistent with SARS-CoV-2 infection (e.g. atypical pneumonia,&#xD;
             organizing pneumonia, ground glass opacities) or acute respiratory distress syndrome&#xD;
             (ARDS) within 7 days of diagnosis of SARS-CoV-2 infection.&#xD;
&#xD;
          -  A negative pregnancy test in women of child-bearing age.&#xD;
&#xD;
          -  If a woman is of child-bearing age, she must be willing to use an effective method of&#xD;
             contraception for 28 days after the final dose of isavuconazole per manufacturer&#xD;
             instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anticipated transfer to another medical center that is not a study site within hours&#xD;
             of admission to the ICU.&#xD;
&#xD;
          -  Pregnancy based on a positive human chorionic gonadotropin (HCG) test from serum or&#xD;
             urine.&#xD;
&#xD;
          -  Patient who is breastfeeding and unable to discontinue breastfeeding while taking the&#xD;
             study drug.&#xD;
&#xD;
          -  Patients with a diagnosis of invasive aspergillosis/detection of Aspergillus spp. by&#xD;
             culture from sputum, TA, BA, or BALF or positive GM from serum or BALF at time of&#xD;
             screening or randomization.&#xD;
&#xD;
          -  History of invasive aspergillosis within the prior six months.&#xD;
&#xD;
          -  Patients with a known intolerance or hypersensitivity to isavuconazole or other azole&#xD;
             agents.&#xD;
&#xD;
          -  History of familial short QT syndrome.&#xD;
&#xD;
          -  Patients that are being treated with mold-active antifungal agents for invasive&#xD;
             aspergillosis or another invasive fungal infection.&#xD;
&#xD;
          -  Patients with severe hepatic impairment or liver cirrhosis (Child C) should be&#xD;
             excluded from the study unless the treating physicians feel the benefits of treatment&#xD;
             outweigh the risks.&#xD;
&#xD;
          -  Treatment with Lopinavir/ritonavir for HIV infection.&#xD;
&#xD;
          -  Prohibited Medications&#xD;
&#xD;
          -  Co-administration with a strong CYP3A4 inhibitor or high-dose ritonavir as they may&#xD;
             alter the plasma concentration of isavuconazole.&#xD;
&#xD;
          -  Co-administration with a strong CYP3A4 inducer such as rifampin, carbamazepine, St.&#xD;
             John's wort, or long acting barbiturates.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Jenks, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Thompson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Hoenigl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Jenks, MD, MPH</last_name>
    <phone>1-800-926-8273</phone>
    <email>jjenks@health.ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alpesh Amin, MD, MBA</last_name>
      <email>anamin@hs.uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lanny Hsieh, MD</last_name>
      <email>llhsieh@hs.uci.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>George Thompson, MD</last_name>
      <email>grthompson@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeffrey Jenks, MD, MPH</last_name>
      <email>jjenks@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert Owens, MD</last_name>
      <email>rowens@health.ucsd.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jeffrey Jenks, MD, MPH</investigator_full_name>
    <investigator_title>Assoc Physician</investigator_title>
  </responsible_party>
  <keyword>Isavuconazole</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Anti-infective Agents</keyword>
  <keyword>Coronavirus-associated Invasive Pulmonary Aspergillosis</keyword>
  <keyword>CAPA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isavuconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

